Eight Roads portfolio company SONOSEMI, an emerging energy-based endovascular therapy platform in China, announced that the company has raised several hundred million yuan in Series A financing. Eight Roads continues to participate in this round together with other investors.

The proceeds will be used for the company’s R&D pipeline expansion, manufacturing capacity development, clinical trials, and clinical education.

Founded in 2020 and headquartered in Shenzhen, SONOSEMI is an emerging energy-based endovascular therapy platform, starting from intravascular lithotripsy technology (IVL) for endovascular calcification treatment. The company’s proprietary coronary IVL system has kicked off the clinical trial in China, as the first domestic player, and the trial is progressing rapidly.

Dr. Shi Lei, Partner of Eight Roads Ventures China, said: “Congratulations to Bin Liu and the SONOSEMI team. Eight Roads is always looking to support leading Chinese MedTech companies with a global perspective. Endovascular device is our key focus in MedTech investment. SONOSEMI’s innovation and excellent execution have further consolidated its business foundation and established its leading market position. We look forward to working closely with the company and other shareholders in the future.”

In 2021, Eight Roads participated in the company’s Series Pre-A financing.